Trial Profile

Phase 2 Study of SERCA2a Gene Transfer in Patients With Severe Heart Failure

Status: Discontinued

Phase of Trial: Phase II

Latest Information Update: 07 Nov 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs SERCA 2a gene therapy (Primary)
Indications Heart failure
Focus Therapeutic Use
Acronyms AGENT-HF

Most Recent Events

10 Apr 2017 Primary endpoint (left ventricular end-systolic volume measured by CT-Scan) has not been met, according to the Results published in the European Journal of Heart Failure.
10 Apr 2017 Results published in the European Journal of Heart Failure
09 May 2016 Status changed from active, no longer recruiting to discontinued.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com